Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor

Cancer Research

Volumn 60, Issue 5, 2000, Pages 1326-1331

  Kishi, Kazushi ^a   Petersen, Sven ^a   Petersen, Cordula ^a   Hunter, Nancy ^a   Mason, Kathryn ^a   Masferrer, Jaime L ^b   Tofilon, Philip J ^a   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Pharma Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION; RADIATION DOSE; TUMOR;

ANIMALS; CELL DIVISION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ISOENZYMES; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SARCOMA, EXPERIMENTAL; SULFONAMIDES;

EID: 0034162780     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Masferrer, J. L., Isakson, P. C., and Seibert, K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol. Clin. N. Am., 25: 363-372, 1996.
2. Pairet, M., and Engelhardt, G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam. Clin. Pharmacol., 10: 1-17, 1996.
3. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst., 90: 1609-1620, 1998.
4. Sheng, H., Williams, C. S., Shao, J., Liang, P., DuBois, R. N., and Beauchamp, R. D. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J. Biol. Chem., 273: 22120-22127, 1998.
5. Subbaramaiah, K., Altorki, N., Chung, W. J., Mestre, J. R., Sampat, A., and Dannenberg, A. J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem., 274: 10911-10915, 1999.
6. Tsujii, M., Kawarto, S., and DuBois, R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA, 94: 3336-3340, 1997.
7. Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., Soslow, R. A., Masferrer, J. L., Woerner, B. M., Koki, A. T., and Fahey, T. J., III. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res., 59: 987-990, 1999.
8. Uefuji, K., Ichikura, T., Mochizuki, H., and Shinomiya, N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J. Surg. Oncol., 69: 168-172, 1998.
9. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., and Hla, T. Expression of cyclooxygenase-1 and-2 inhuman colorectal cancer. Cancer Res., 55: 3785-3789, 1995.
10. Battu, S., Rigaud, M., and Beneytout, J. L. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL. 19A. Anticancer Res., 18: 3579-3583, 1998.
11. Chan, G., Boyle, J. O., Yang, E. K., Zhang, F., Sacks, P. G., Shah, J. P., Edelstein, D., Soslow, R. A., Koki, A. T., Woerner, B. M., Masferrer, J. L., and Dannenberg, A. J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59: 991-994, 1999.
12. Elder, D. J., Halton, D. E., Hague, A., and Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory-drug: independence from COX-2 protein expression. Clin. Cancer Res., 3: 1679-1683, 1997.
13. Kalgutkar, A. S., Crews, B. C., Rowlinson, S. W., Garner, C., Seibert, K., and Marnett, L. J. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science (Washington DC), 280: 1268-1270, 1998.
14. Takelo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part 1). J. Natl. Cancer Inst., 90: 1529-1536, 1998.
15. Hawkey, C. J. COX-2 inhibitors. Lancet. 353: 307-314, 1999.
16. Pillsbury, H. C., Webster, W. P., and Rosenman, J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch. Otolaryngol. Head Neck Surg., 112: 552-553, 1986.
17. Milas, L., and Hanson, W. R. Eicosanoids and radiation. Eur. J. Cancer, 31A: 1580-1585, 1995.
18. Hanson, W. R., and Thomas, C. 16, 16-Dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. Radiat. Res., 96: 393-398, 1983.
19. Sochanowicz, B., and Szumiel, I. Arachidonic acid metabolism in murine lymphoma cell sublines differing in radiation sensitivity. Prostaglandins Leukot. Essent. Fatty Acids, 55: 241-247, 1996.
20. Furuta, Y., Hunter, N., Barkley, T., Jr., Hall, E., and Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res., 48: 3008-3013, 1988.
21. Milas, L., Furuta, Y., Hunter, N., Nishiguchi, I., and Runkel, S. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res., 50: 4473-4477, 1990.
22. Palayoor, S. T., Bump, E A., Calderwood, S. K., Bartol, S., and Coleman, C. N. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin. Cancer Res., 4: 763-771, 1998.
23. Milas, L., Kishi, K., Hunter, N., Mason, K., Masferrer, J. L., and Tofilon, P. J. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst., 91: 1501-1504, 1999.
24. Furuta, Y., Hall, E. R., Sanduja, S., Barkley, T., Jr., and Milas, L. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res., 48: 3002-3007, 1988.
25. Milas, L., Hunter, N., Mason, K., and Withers, H. R. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res., 34: 61-71, 1974.
26. Withers, H. R., and Elkind, M. M. Radiosensitivity and fractionation response of crypt cells of mouse jejunum. Radiat. Res., 38: 598-613, 1969.
27. Stone, H. B. Leg contracture in mice: an assay of normal tissue response. Int. J. Radiat. Oncol. Biol. Phys., 10: 1053-1061, 1984.
28. Kujubu, D. A., and Herschman, H. R. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem., 267: 7991-7994, 1992.
29. Salvemini, D., and Masferrer, J. L. Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies. Methods Enzymol., 269: 12-25, 1996.
30. Stephens, L. C. Ang, K. K., Schultheiss, T. E., Milas, L., and Meyn, R. E. Apoptosis in irradiated murine tumors. Radiat. Res., 127: 308-316, 1991.
31. Milas, L., Hunter, N. R., Kurdoglu, B., Mason, K. A., Meyn, R. E., Stephens, L. C., and Peters, L. J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol., 35: 297-303, 1995.
32. Runkel, S., Hunter, N., and Milas, L. An intradermal assay for quantification and kinetics studies of tumor angiogenesis in mice. Radiat. Res., 126: 237-243, 1991.
33. Leung, K. H., and Mihich, E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature (Lond.), 288: 597-600, 1980.
34. Brunda, M. J., Herberman, R. B., and Holden, H. T. Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol., 124: 2682-2687, 1980.
35. Moskowitz, M. A., and Coughlin, S. R. Clinical applications of prostaglandins and their inhibitors. Stroke, 12: 882-886, 1981.
36. Ziehe, M., Jones, J., and Gullino, P. M. Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst., 69: 475-482, 1982.
37. Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L. B., and Lipsky, P. E. Cyclooxygenase in biology and disease [see comments]. FASEB J., 12: 1063-1073, 1998.
38. Chiarugi, V., Magnelli, L., and Gallo, O. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int. J. Mol. Med., 2: 715-719, 1998.
39. Hejna, M., Raderer, M., and Zielinski, C. C. Inhibition of metastases by anticoagulants. J. Natl. Cancer Inst., 91: 22-36, 1999.
40. Honn, K. V., Bockman, R, S., and Marnett, L. J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins, 21: 833-864, 1981.
41. Sheng, H., Shao, J., Kirkland, S. C, Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., and DuBois, R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Investig., 99: 2254-2259, 1997.
42. Meyn, R. E., Stephens, L. C., Ang, K. K., Hunter, N. R., Brock, W. A., Milas, L., and Peters, L. J. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int. J. Radiat. Biol., 64: 583-591, 1993.
43. Schimming, R., Mason, K. A., Hunter, N., Weil, M., Kishi, K., and Milas, L. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother. Pharmacol., 43: 165-172, 1999.
44. Masferrer, J. L., Leahy, J. M., Lei, Y., Moore, R., Flickinger, A., Zweifel, B., Koki, A. T., and Seibert, K. Celecoxib: a specific COX-2 inhibitor with anti-angiogenetic and anti-cancer activities. Proc. Am. Assoc. Cancer Res., 40: 396, 1999.
45. Gorski, D. H., Mauceri, H. J., Salloum, R. M., Gately, S., Hellman, S., Beckett, M. A., Sukhatme, V. P., Soff, G. A., Kufe, D. W., and Weichselbaum, R. R. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res., 58: 5686-5689, 1998.